PharmaMar corrects after the euphoria of its drug against omicron and falls by 13%

From the highest to the bottom of the table. That has been the path taken by PharmaMar in the last two trading days. While the company posted a rise of almost 18% on Tuesday, this Wednesday it fell by about 13%, to 55.76 euros per share. A crash very far from Naturgy or Amadeus falls, who lose between 1.5% and 2% this session.

The correction comes after the euphoria generated among investors by the publication in ‘Science’ of the results of a study that showed that Aplidin offers powerful antiviral activity against all variants of covid, including omicron, as reported by the firm to the National Securities and Markets Commission (CNMV).

At the end of 2021, PharmaMar appreciated more than 12.5%, and its titles are at 9.5% of the maximums reached in August 2021, when they traded at 61.04 euros per title. At the start of the year, the figures have turned to the red, and the firm has already left more than 2%.

However, the study is still in the early stages, and there is great competition in the international arena in order to find the best solutions in the fight against the coronavirus. “Analysts do not usually take into account the results in phase 1. In a normal situation, this news should go practically unnoticed by the stock,” explained Pedro Echeguren, from Bankinter’s team of analysts to this newspaper.

Disclaimer: If you need to update/edit/remove this news or article then please contact our support team Learn more